James Investment Research’s PDL BioPharma, Inc. PDLI Stock Holding History

James Investment Research’s Portfolio PDLI Stock Details PDLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q3	–	Sell	-228,950	Closed	-$1.47M	–	520
2015 Q2	$1.47M	Sell	228,950 -110,350	-33%	-$739K	0.03%	207
2015 Q1	$2.39M	Sell	339,300 -78,820	-19%	-$571K	0.06%	186
2014 Q4	$3.22M	Sell	418,120 -37,395	-8%	-$296K	0.09%	155
2014 Q3	$3.4M	Sell	455,515 -30,905	-6%	-$287K	0.11%	149
2014 Q2	$4.71M	Buy	486,420 +12,805	+3%	+$114K	0.15%	127
2014 Q1	$3.94M	Buy	473,615 +53,315	+13%	+$457K	0.13%	139
2013 Q4	$3.55M	Buy	420,300 +28,100	+7%	+$237K	0.11%	150
2013 Q3	$3.13M	Buy	392,200 +203,435	+108%	+$1.64M	0.12%	149
2013 Q2	$1.46M	Buy	+188,765	New	+$1.47M	0.06%	176

Other funds holding PDLI

ACM

Americafirst Capital Management Roseville, California $74M AUM 13.49% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

GAM

Gotham Asset Management New York $32.7B AUM 27.65% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

AAM

Advisors Asset Management Monument, Colorado $6.01B AUM 24.74% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

James Investment Research's PDLI Position: Q3 2015 in Review

James Investment Research sold out of PDL BioPharma, Inc. (PDLI) in Q3 2015, closing a stake of 228,950 shares — an estimated $1.47M sold.

James Investment Research first reported a position in PDLI in Q2 2013 and held it in 9 quarters. The position peaked at $4.71M in Q2 2014. 213 funds tracked by Wall St. Rank hold PDLI as of Q3 2015.

James Investment Research reported no remaining PDL BioPharma, Inc. position as of Q3 2015 after selling out during the quarter.
James Investment Research sold 228,950 PDL BioPharma, Inc. shares in Q3 2015, an estimated $1.47M.
James Investment Research first reported a position in PDL BioPharma, Inc. in Q2 2013 and held it in 9 quarters.
James Investment Research's PDL BioPharma, Inc. position peaked at $4.71M in Q2 2014.
213 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q3 2015.

Based on James Investment Research's 13F filing for Q3 2015, filed 5 Oct 2015.